top of page

Developing A Class Of Newly Discovered T-cells To Make Cell Therapies More Durable, Longer-lasting and Safer For Patients

RORABio is developing a first-in-class T-cell platform for targeting indications across cancer and infectious diseases. The platform consists of a newly discovered, long-lived, stem-like memory cell population that we call “RORA-Tscm”.  Since presence of RORA-Tscm cells correlates with reduced tumor burdens in animal models and is emerging as a hallmark of better clinical outcomes for some patients,     we are developing these cells in two formats: 1) modified with a mono- or bispecific chimeric receptor antigen (CAR) to make new CAR-T drugs with potential to be more durable, safer and long-lasting, and 2) as a stand-alone therapy to reconstitute the immune system of HIV infected patients.


Manufacturing Process

RORA-Tscm cells can be scalably expanded to homogeneity under GLP- and GMP-grade like conditions

Superior Stem-ness
and Durability

RORA-Tscm cells are associated with positive clinical outcomes in patients

Flexible T-cell Platform For Making New Cell Therapies

RORA-Tscm cells can be used alone or for making genetically engineered biologics (e.g., expressing a CAR or  edited/deleted gene) 


October 10, 2023

NIH will host a meeting entitled Strategies For An HIV Cure 2023 from October 12-13, 2023. The meeting will feature presentations from ten NIH Martin Delaney Collaboratories for HIV Cure Research. The event will also include presentations from the two Centers for Innovative HIV/AIDS Vaccine and Cure Research (CIAVCR). It will also feature abstract-driven poster sessions. Our Chief Scientific Officer, Dr. Rafick Sekaly, and our VP Clinical Opps, Dr. Ashish Sharma, will be attending and presenting at the meeting.
For more information

bottom of page